Form 8-K

8-K — ANI PHARMACEUTICALS INC

Accession: 0001023024-26-000054

Filed: 2026-05-13

Period: 2026-05-13

CIK: 0001023024

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ani-20260513.htm (Primary)

EX-99.1 (may2026anipcorporatepres.htm)

GRAPHIC (may2026anipcorporatepres001.jpg)

GRAPHIC (may2026anipcorporatepres002.jpg)

GRAPHIC (may2026anipcorporatepres003.jpg)

GRAPHIC (may2026anipcorporatepres004.jpg)

GRAPHIC (may2026anipcorporatepres005.jpg)

GRAPHIC (may2026anipcorporatepres006.jpg)

GRAPHIC (may2026anipcorporatepres007.jpg)

GRAPHIC (may2026anipcorporatepres008.jpg)

GRAPHIC (may2026anipcorporatepres009.jpg)

GRAPHIC (may2026anipcorporatepres010.jpg)

GRAPHIC (may2026anipcorporatepres011.jpg)

GRAPHIC (may2026anipcorporatepres012.jpg)

GRAPHIC (may2026anipcorporatepres013.jpg)

GRAPHIC (may2026anipcorporatepres014.jpg)

GRAPHIC (may2026anipcorporatepres015.jpg)

GRAPHIC (may2026anipcorporatepres016.jpg)

GRAPHIC (may2026anipcorporatepres017.jpg)

GRAPHIC (may2026anipcorporatepres018.jpg)

GRAPHIC (may2026anipcorporatepres019.jpg)

GRAPHIC (may2026anipcorporatepres020.jpg)

GRAPHIC (may2026anipcorporatepres021.jpg)

GRAPHIC (may2026anipcorporatepres022.jpg)

GRAPHIC (may2026anipcorporatepres023.jpg)

GRAPHIC (may2026anipcorporatepres024.jpg)

GRAPHIC (may2026anipcorporatepres025.jpg)

GRAPHIC (may2026anipcorporatepres026.jpg)

GRAPHIC (may2026anipcorporatepres027.jpg)

GRAPHIC (may2026anipcorporatepres028.jpg)

GRAPHIC (may2026anipcorporatepres029.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ani-20260513.htm · Sequence: 1

ani-20260513

0001023024FALSE00010230242026-05-132026-05-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): May 13, 2026

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-31812 58-2301143

(State or other jurisdiction of

incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

104 Carnegie Center Drive, Suite 300

Princeton, New Jersey

08540

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (609) 759-1810

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which

registered

Common Stock ANIP Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure

On May 13, 2026, ANI Pharmaceuticals, Inc. (the “Company”) published an updated investor presentation to the investor relations section of its website. The Company may use the updated investor presentation in various meetings with investors and analysts from time to time. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*

Item 9.01 Exhibits

(d)Exhibits

Exhibit

No. Description

99.1

Investor Presentation, dated May 2026

104 Cover Page Interactive Data File (embedded with the Inline XBRL document)

*The information in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 13, 2026 ANI PHARMACEUTICALS, INC.

By: /s/ Stephen P. Carey

Name: Stephen P. Carey

Title: Senior Vice President Finance and Chief Financial Officer

EX-99.1

Filename: may2026anipcorporatepres.htm · Sequence: 2

may2026anipcorporatepres

© 2026 ANI Pharmaceuticals, Inc. 2 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The guidance included herein was provided on the Company's earnings conference call on May 8, 2026. Investors accessing this presentation subsequent to May 8, 2026 are cautioned that the Company is neither reconfirming this guidance as of any date subsequent to May 8, 2026 nor assuming any obligation to update or revised such guidance. Any statements that are not historical facts, including statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are forward-looking statements. These statements are often, but are not always, made through the use of words or phrases such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words or other comparable terminology. These statements may include, but are not limited to, statements concerning our planned future operations, strategies and growth potential; our strategy and future operations, including with respect to our share repurchase program; our future financial position and performance, including our expectations regarding our forecasted revenue (including revenue from licensing, royalties and sales) and our forecasted adjusted non-GAAP EBITDA and adjusted non-GAAP gross margin, as well as our estimates of our expenses and capital requirements; our development pipeline, including the structure, focus, success, cost and timing of our development activities, including nonclinical studies and clinical trials, and the reporting of data from those activities; expected timeframes for the submission of new drug applications, abbreviated new drug applications, or supplemental new drug applications to the U.S. Food and Drug Administration (the “FDA”) and the number of product launches we expect to be able to complete in a given timeframe; our expectations regarding the size of patient populations, market acceptance and clinical utility of our products and product candidates, if approved; anticipated growth opportunities for Cortrophin Gel and ILUVIEN; and the commercialization and potential anticipated sales of our products. Uncertainties and risks may cause our actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of our approved products, including Cortrophin Gel and ILUVIEN, to achieve commercialization at levels of market acceptance that will allow us to maintain profitability; ou r manufacturing capabilities and our ability to comply with significant regulations with respect to the manufacture of our products or, where applicable, our reliance on third parties to do the same; supply chain and inventory expectations, and our and our partners’ ability to meet anticipated demand; selling and marketing strategies and associated costs to support the sales of our branded products, including Purified Cortrophin® Gel (Repository Corticotropin Injection USP) (“Cortrophin Gel”) and ILUVIEN® (“ILUVIEN”); increased costs and potential loss of revenues if we need to change suppliers due to the limi ted number of suppliers for our raw materials, active pharmaceutical ingredients, expedients, and other materials; delays and disruptions in the production of our approved products as a result of our reliance on single source third party contract manufacturing supply for certain of our key products, including Cortrophin Gel and ILUVIEN; the success of competing therapies that are or may become available; our strategic initiatives, including acquisitions, strategic alliances and collaborations, and our ability to realize the intended benefits of such initiatives; our ability to attract and retain key personnel; our expectations and uncertainties regarding future pricing, coverage and reimbursement for our products; the impact of new or modified laws or regulations, and the application or implementation thereof; our ability to obtain, protect and enforce our intellectual property; and general economic, industry, geopolitical and market conditions, such as military conflict or war, inflation and financial institution instability, or the impact of global pandemics on our business. Any forward-looking statements in this presentation are based on the reasonable beliefs of our management as well as assumptions made by and information currently available to our management. Forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors, some of which cannot be predicted or quantified, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that might cause such a difference include, but are not limited to, those risks and uncertainties that are described in the Company’s most recent Annual Report on Form 10-K, any subsequent quarterly reports filed by the Company on Form 10-Q, and other periodic reports filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Such statements are based on management’s expectations as of the date of this presentation and involve many risks and uncertainties that could cause our actual results, events or circumstances to differ materially from those expressed or implied in our forward-looking statements. We undertake no obligation to update any forward-looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

© 2026 ANI Pharmaceuticals, Inc. 3 Presentation of financial information Non-GAAP Financial Measures Adjusted non-GAAP EBITDA ANI’s management considers adjusted non-GAAP EBITDA to be an important financial indicator of ANI’s operating performance, providing investors and analysts with a useful measure of operating results unaffected by non-cash stock-based compensation and differences in capital structures, tax structures, capital investment cycles, ages of related assets, and compensation structures among otherwise comparable companies. Management uses adjusted non-GAAP EBITDA when analyzing Company performance. Adjusted non-GAAP EBITDA is defined as net income, excluding tax expense, interest expense, net, other expense (income), net, depreciation and amortization expense, non-cash stock-based compensation expense, M&A transaction and integration expenses, contingent consideration fair value adjustments, unrealized (gain) loss on our investment in equity securities, expenses incurred and settlement payments received in connection with certain litigation matters, severance expenses, and certain other items that vary in frequency and impact on ANI’s results of operations. Adjusted non-GAAP EBITDA should be considered in addition to, but not in lieu of, net income or loss reported under GAAP. A reconciliation of adjusted non-GAAP EBITDA to the most directly comparable GAAP financial measure is provided within the Appendix. ANI is not providing a reconciliation for the forward-looking full year 2026 adjusted EBITDA guidance because it does not currently have sufficient information to accurately estimate all of the variables and individual adjustments for such reconciliation, including “with” and “without” tax provision information. As such, ANI’s management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results. Adjusted non-GAAP Diluted Earnings per Share ANI’s management considers adjusted non-GAAP diluted earnings per share to be an important financial indicator of ANI’s operating performance, providing investors and analysts with a useful measure of operating results unaffected by the non-cash stock-based compensation, non-cash interest expense, depreciation and amortization, M&A transaction and integration expenses, contingent consideration fair value adjustment, unrealized (gain) loss on our investment in equity securities, expenses incurred and settlement payments received in connection with certain litigation matters, severance expense, and certain other items that vary in frequency and impact on ANI’s results of operations. Management uses adjusted non-GAAP diluted earnings per share when analyzing Company performance. Non-GAAP Adjusted Diluted Weighted-Average Shares Outstanding excludes certain dilutive shares related to the convertible senior notes as they are intended to be covered by our capped call transactions. Our outstanding capped call transactions are intended to offset the dilutive effect of the convertible senior notes recognized in the calculation of GAAP diluted EPS in this reporting period in full, and therefore shares have been excluded from the calculation of the Non-GAAP Adjusted Diluted Weighted- Average Shares outstanding. Adjusted non-GAAP diluted earnings per share is defined as adjusted non-GAAP net income, as defined above, divided by the diluted weighted average shares outstanding during the period. Management will continually analyze this metric and may include additional adjustments in the calculation in order to provide further understanding of ANI’s results. Adjusted non-GAAP diluted earnings per share should be considered in addition to, but not in lieu of, diluted earnings (loss) per share reported under GAAP. A reconciliation of adjusted non-GAAP diluted earnings per share to the most directly comparable GAAP financial measure is provided within the Appendix. ANI is not providing a reconciliation for the forward-looking full year 2026 adjusted diluted earnings per share guidance because it does not currently have sufficient information to accurately estimate all of the variables and individual adjustments for such reconciliation, including “with” and “without” tax provision information. As such, ANI’s management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results. Other non-GAAP metrics ANI’s management also considers non-GAAP gross margin to be a financial indicator of ANI’s operating performance, providing investors and analysts with a useful measure of operating results unaffected by non-cash stock-based compensation expense, and certain other items that vary in frequency and impact on ANI’s results of operations. Management uses non-GAAP gross margin when analyzing Company performance. Non-GAAP cost of sales is defined as cost of sales (excluding depreciation and amortization), excluding non-cash stock-based compensation expense, amortization of certain purchase price adjustments, and certain other items that vary in frequency and impact on ANI’s results of operations. Non-GAAP gross margin is defined as adjusted non-GAAP net revenues less non-GAAP cost of sales (excluding depreciation and amortization) divided by non-GAAP net revenues. Non-GAAP cost of sales and Non-GAAP gross margin should be considered in addition to, but not in lieu of, cost of sales and gross margin reported under GAAP. ANI is not providing a reconciliation for the forward-looking full year 2026 adjusted non-GAAP gross margin guidance because it does not currently have sufficient information to accurately estimate all of the variables and individual adjustments for such reconciliation, including “with” and “without” tax provision information. As such, ANI’s management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.”

© 2026 ANI Pharmaceuticals, Inc. 4 ~$1.1B Total net revenue in 2026 A profitable, high-growth biopharmaceutical organization transforming into a leading Rare Disease company • Projecting ~$1.1B in total net revenue in 2026 • 44% YoY increase in 2025 • 26% YoY increase in 2026(1) • Rare Disease business is primary focus • Expected to represent ~60% of total revenues in 2026 • Lead asset, Cortrophin Gel, expected to provide substantial, durable multi-year growth opportunity • Generics business delivering strong cash flows enabled by superior R&D capabilities, operational execution, and U.S. manufacturing 1. Percent change calculated using the midpoint of 2026 financial guidance ranges provided by the Company on May 8, 2026. RARE D ISEASE BRA N D S G E N E R I C S ANI’s virtuous cycle of growth

© 2026 ANI Pharmaceuticals, Inc. 5 Proven track record of delivering top- and bottom-line growth Adjusted Non-GAAP EBITDA ($ millions)(1)Total Company Net Revenues ($ millions) 1. Adjusted Non-GAAP EBITDA is a Non-GAAP financia l measure. See Appendix for a reconciliation to the most directly comparable GAAP financial metr ic. 2. 2022-2026 CAGR calcu lated using the midpoint of full year 2026 guidance provided by the Company on May 8, 2026. 3. Based on 2026 financial guidance provided by the Company on May 8, 2026. $316 $487 $614 $883 $1,080-$1,140 2022 2023 2024 2025 2026E +37% CAGR(2) $56 $134 $156 $230 $285-$300 2022 2023 2024 2025 2026E +51% CAGR(2) (3) (3)

© 2026 ANI Pharmaceuticals, Inc. 6 ACCELERATE ANI’S TRANSFORMATION INTO A LEADING RARE DISEASE COMPANY Cortrophin Gel 2026 priorities to drive long-term growth and value creation • Maximize multi-year growth opportunity by addressing significant unmet need across indications • Build on momentum in underpenetrated specialty indications in nephrology, neurology, rheumatology, ophthalmology and pulmonology • Recently onboarded majority of commercial team for acute gouty arthritis flares • Advance Phase 4 trial to establish further evidence supporting Cortrophin Gel in acute gouty arthritis flares • Continue to evaluate opportunities to enhance patient convenience ILUVIEN • Return to growth by leveraging the commercial and patient access initiatives established in 2025 CONTINUED EXCELLENCE IN GENERICS BUSINESS EXECUTE DISCIPLINED CAPITAL ALLOCATION STRATEGY • Leverage superior R&D capabilities, operational execution, U.S. manufacturing footprint, and business development expertise to continue expanding cash generation • On track to Maintain current cadence of 10-15 launches annually • Explore opportunities to expand scope and scale of Rare Disease business • Investing in dedicated organization for Cortrophin Gel in gout • Invest high single-digit percentage of Generics revenue into R&D

© 2026 ANI Pharmaceuticals, Inc. 7 Q1 2026 and recent business highlights 1. Totals may not sum due to rounding. 2. Adjusted Non-GAAP EBITDA is a Non-GAAP financia l measure. See Appendix for a reconciliation to the most directly comparable GAAP financial metr ic. 3. Includes Cortrophin Gel, ILUVIEN, Brands, and Brand royalties and other revenues. 4. Includes Generic pharmaceutical products and other generic revenues. • Strong top- and bottom-line growth supported by solid performance across each business unit • Continued momentum in demand for Cortrophin Gel • Monetized innovative IP, creating new stream of royalty revenue • Raising 2026 financial guidance for total net revenues and adjusted EBITDA • Board authorized new $100M share repurchase program $94.1 $128.2 $103.0 $109.2 1Q25 1Q26 +20% $197.1 $237.5 $50.7 $63.0 1Q25 1Q26 Adjusted Non-GAAP EBITDA ($M)(2) +24% Total Net Revenues ($M)(1) Rare Disease and Brands(3) Generics and Other(4)

© 2026 ANI Pharmaceuticals, Inc. 8 Establishing collaborations to drive future value for our stakeholders Out-licensed intellectual property to Harmony Biosciences in January 2026 Harmony to utilize IP to expand its intellectual property estate for pitolisant and to develop a novel formulation Low single digit royalties on pitolisant-based products $10M payment upon achievement of certain development milestones; expected to be achieved in 2Q26 and 3Q26 $15M upfront license fee recognized in 1Q26

© 2026 ANI Pharmaceuticals, Inc. 9 1. Adjusted Non-GAAP EBITDA, Adjusted Non-GAAP Diluted EPS, and Adjusted Non-GAAP Gross Margin are Non-GAAP f inancial measures. 2. For full year 2026 guidance, Adjusted Non-GAAP Diluted EPS is defined as adjusted Non-GAAP net income divided by the diluted weighted average shares outstanding during the period ("Non-GAAP Adjusted Diluted Weighted- Average Shares Outstanding"). Non-GAAP Adjusted Diluted Weighted-Average Shares Outstanding excludes certain dilut ive shares related to the senior convertible notes as they are intended to be covered by our capped call transactions. 3. Blended royalty rate due to Merck for Cortrophin Gel net sales expected to be in high-20 percent range in 2026. 4. Does not assume any share repurchases in 2026. 5. Based on 2026 f inancial guidance provided by the company on May 8, 2026 YoY Growth $1,055 - $1,115 22 - 29% $540 - $575 55 - 65% $78 - $83 4 - 11% $275 - $290 24 - 31% $8.83 - $9.34 16 - 23% Metric ($ millions, except EPS) Net Revenue (Total Company) Cortrophin Gel Net Revenue ILUVIEN Net Revenue Adjusted Non-GAAP EBITDA(1) Adjusted Non-GAAP Diluted EPS(1)(2) Prior 2026 Guidance 2026 Financial Guidance5 Reflects significant top- and bottom-line growth 2026 adjusted non-GAAP gross margin expected to be 59.9% - 60.9%(3) $1,080 - $1,140 $540 - $575 $78 - $83 $285 - $300 $9.19 - $9.69 Current 2026 Guidance Anticipates 21.5M – 21.8M shares outstanding for the purpose of calculating full year 2026 adjusted non-GAAP diluted EPS(4)

© 2026 ANI Pharmaceuticals, Inc. 11 Rare Disease business represents primary driver of growth; expected to account for ~60% of revenues in 2026 1. Percent change calculated based on the midpoint of 2026 financial guidance range provided by the Company on May 8, 2026. 2. Alimera acquisition occurred in September 2024; ILUVIEN revenue only represents partial year of ownership. 3. Represents 2026 financial guidance ranges provided by the Company on May 8, 2026. Rare Disease Net Revenues ($ millions) $198 $348 $540 - $575 $32 $75 $78 - $83 2022 2023 2024 2025 2026E $230 $423 $42 $112 $618 - $658 (3) Cortrophin Gel ILUVIEN +84% +51%(1) (2)

© 2026 ANI Pharmaceuticals, Inc. 12 Cortrophin Gel: lead rare disease asset Acceleration in momentum across new patient starts and dispensed volumes Potential for strong multi-year growth as key indications are significantly underpenetrated Broad growth across all targeted specialties: rheumatology, nephrology, neurology, pulmonology and ophthalmology Prescribing in acute gouty arthritis flares expected to be a key growth driver in 2026; represents ~18% of total utilization

© 2026 ANI Pharmaceuticals, Inc. 13 2021 2022 2023 2024 2025 $594M $558M $537M $684M $1.0B ACTH MARKET SALES -6% -4% +27%YoY Growth +50% Acthar Gel Purified Cortrophin® Gel >$1.3B +30% 2026(1) Overall ACTH market growth driven by continued expansion into key indications • Expect continued strong multi- year growth potential driven by large market opportunity as key indications remain significantly underpenetrated • Proven ability to reach new HCPs and patients with approximately half of Cortrophin Gel prescribers naive to the ACTH category before prescribing Cortrophin Gel 1. Based on the sum of 2026 Cortrophin Gel net revenue guidance and Keenova Therapeutics’ 2026 guidance for Acthar Gel per its fourth quarter 2025 earnings release (March 31, 2026). +24% CAGR

© 2026 ANI Pharmaceuticals, Inc. 14 Diagnosed ~9,900,0001 ~500,000 addressable annual flares ~285,000 addressable patients Acute Gout Flares Cortrophin Gel has strong multi-year growth potential with addressable patient populations across indications significantly under-penetrated ~36% receive treatment annually2 1.5 – 2 average flares per year3 ~8% receive an injectable flare treatment4 Diagnosed ~750,0005 Multiple Sclerosis Flares 1-2.2 average flares per year6,7 25% of patients do not respond to a steroid8 Diagnosed ~1,600,0009 Rheumatoid Arthritis 17-25% experience a flare annually10,11 Up to 30% of patients do not respond to a steroid12 Diagnosed ~35,00020 Nephrotic Syndrome (proteinuria reduction) 12.5% – 20% of patients do not respond to a steroid21,22 Diagnosed ~175,00013-15 Sarcoidosis 25-42.5% of patients are treated13,16 10-25% of patients require a second line therapy17-19 ~300,000 addressable annual flares ~187,500 addressable patients ~100,000 addressable annual flares ~480,000 addressable patients ~10,000 addressable patients ~6,000 addressable patients * A ll re ferences provided in appendix. Addressable patient populations shared for select ind ications.

© 2026 ANI Pharmaceuticals, Inc. 15 $42 $112 $198 $348 $540 - $575 2022 2023 2024 2025 2026E Cortrophin Gel Net Revenues ($ millions) Investing in Cortrophin Gel to build momentum in 2026 and beyond 1. Year-over-year growth calculated based on the midpoint of 2026 financial guidance range provided by the Company on May 8, 2026. 2. Represents 2026 financial guidance provided by the Company on May 8, 2026. (2) +76% +60%(1) Investing in high ROI commercial initiatives • Focus efforts to continue momentum established in Nephrology, Neurology, Rheumatology and Pulmonology as the ACTH market expands • Expanding rare disease organization by ~90-people dedicated to gout that targets primary care and podiatrist offices, full organization expansion completed and operational by the end of June 2026 • Realizing synergies with integrated ophthalmology team Generating scientific and clinical evidence • Advancing Phase 4 clinical trial of Cortrophin Gel in acute gouty arthritis flares • Robust pipeline of investigator-initiated trials across disease states • Continued investment in preclinical data and publications Enhancing convenience • Launched Pre-Filled Syringe in 2025 • Continuing to evaluate opportunities to enhance patient convenience

© 2026 ANI Pharmaceuticals, Inc. 16 Capturing sizable additional opportunity in gout through commercial organization expansion * A ll re ferences provided in appendix. Addressable patient populations shared for select ind ications. • Focus on most severe patients: ~285,000 who are currently treated with injectables for their flares • Need for new treatments for those patients not well served by first line options • Co-morbidities may limit certain treatment options • Only approved ACTH therapy to treat acute gouty arthritis flares • In 2025, ran successful pilots across 10 territories in primary care and podiatry • Prefilled syringe and subcutaneous option for Cortrophin self- administration enables flare readiness, unlike most injectable options • Rare Disease commercial organization expansion targeting high priority PCPs and podiatrists who see most severe acute gouty arthritis patients to be in the field by end of 2Q26 • Majority of commercial team has been onboarded Diagnosed ~9,900,0001 Acute Gout Flares ~36% receive treatment annually2 1.5 – 2 average flares per year3 Large underpenetrated market opportunity Successful track record in Gout Our approach to serving more patients ~8% receive an injectable flare treatment4 ~285,000 patients ~500,000 addressable annual flares

© 2026 ANI Pharmaceuticals, Inc. 17 ILUVIEN is a long-acting ocular therapy approved for DME and chronic NIU-PS 36-months of continuous therapy via CONTINUOUS MICRODOSING of fluocinolone acetonide (FAc) in patients with retinal disease Diabetic Macular Edema (DME): • Chronic disease that is the leading cause of vision loss in diabetic patients; ~4% of diabetic patients develop clinically significant macular edema • >50,000 patients in the U.S. are not well served by anti-VEGF therapy; <5,000 patient starts annually for DME in the U.S. • Strong global clinical evidence in DME supported by NEW DAY study results Chronic non-infectious uveitis affecting the posterior segment (NIU-PS): • Inflammation of the eye that can lead to pain, visual impairment, and vision loss • >75,000 patients in the U.S. are candidates for treatment, and steroids are the standard of care; <5,000 patient starts annually for NIU-PS in the U.S.

© 2026 ANI Pharmaceuticals, Inc. 18 Returning ILUVIEN to growth by leveraging established commercial and patient access initiatives NEW DAY study results in DME published in Ophthalmology Expect to present SYNCHRONICITY trial results in NIU-PS at medical meeting in 3Q 2026 Growing use of alternative access channels to navigate market access challenges for Medicare patients

© 2026 ANI Pharmaceuticals, Inc. 20 $210 $269 $301 $384 2022 2023 2024 2025 Robust, diversified pipeline and new product launch execution • Robust pipeline in place with goal to deliver ~10-15 new product launches annually; 6 products launched YTD; ANI holds #2 CGT filing position • Invest high single-digit percentage of Generics revenue into Generics R&D to support business • Diversified portfolio of ~125 product families and largest product expected to account for less than approximately 6% of Generics revenues in 2026 Strong operational backbone with a focus on cost efficiency • Three U.S. based manufacturing sites with strong GMP track record; all sites currently in VAI or NAI status • Manufactured and supplied over 2.5 billion doses of therapeutics in last 12 months(1) • Systematic approach to reducing raw materials and finished goods costs and lean corporate spend Generics business driving strong cash flow generation with superior R&D capabilities, U.S. manufacturing footprint, and operational excellence Generics Net Revenues2 ($ millions) +12% +28% 1. Per IQVIA NSP Sales data - MAT December 2025 data. 2. Reflects generic pharmaceutical products.

© 2026 ANI Pharmaceuticals, Inc. 22 United States 93% Europe 2% India 2% Others 3% United States 48% Europe 26% India 18% China 5% Others 3% Over 90% of ANI’s revenues come from finished goods manufactured in the U.S.; ~95% of revenues from products sold in the U.S. API by Country of Origin Finished Goods (FG) by Country of Origin % of Revenues % of Revenues ~95% of revenues from products sold in the U.S. NOTE: Statistics on this slide based upon in ternal analysis utilizing estimated / projected fu ll year 2025 Revenue, procurement, manufacturing and other data as prepared June 2025

© 2026 ANI Pharmaceuticals, Inc. 23 U.S.-based manufacturing footprint with strong GMP track record Baudette, MN 130k sf Baudette, MN Containment Facility - 47k sf East Windsor, NJ 120k sf Facility Overview and Capabilities • Manufacturing, packaging, warehouse • Schedule CII vault & CIII cage space • Lab space - R&D/analytical testing • Solutions, suspensions, topicals, tablets, capsules, and powder for suspension • DEA-licensed for Schedule II controlled substances • Manufacturing, packaging, warehouse • Low-humidity suite for moisture-sensitive compounds • Fully-contained high potency facility for hormone, steroid, and oncolytic products • DEA Schedule III capability • 100K ft2 of manufacturing, packaging, lab, warehouse, and administrative space • 20K ft2 expansion added 15 new manufacturing suites and new QC lab • Solid oral tablets and capsules, liquid suspensions and solutions, powder for oral suspension, controlled substances as well as containment & nano-milling • API development & low volume production Annual Capacity • Solid Dose ~2.5BN doses • Liquid Unit ~23MM doses • Liquids ~20MM bottles • Powder ~4MM bottles • Tablets ~2.5BN doses • Capsules ~150MM doses • Blisters ~ 45MM doses • Tablets & Capsules ~3.0BN doses • Packaged Units ~20MM units • Liquids ~10MM bottles • Powder ~ 2MM bottles ; Semi Solids GMP Five FDA inspections since 2013 Latest FDA inspection – December 2024 Current site status: VAI Seven DEA inspections since 2013 Latest DEA inspection – August 2023 Current site status: VAI Seven FDA inspections since 2017, Four DEA inspections since 2016 Latest FDA inspection – January 2024 Current site status: NAI status (zero 483s)

© 2026 ANI Pharmaceuticals, Inc. 25 ANI well positioned to deliver long-term growth and value creation • Rare Disease expected to represent ~60% of total revenue in 2026 • Lead asset, Cortrophin Gel, expected to deliver +60% YoY growth in 2026 with substantial, multi-year growth opportunity(1) • Strong Generics cash flows further enables investments in Rare Disease business VIRTUOUS CYCLE OF GROWTH DRIVES TRANSFORMATION INTO A LEADING RARE DISEASE COMPANY 1. Based on the midpoint of 2026 financial guidance ranges provided by the Company on May 8, 2026. 2. Adjusted Non-GAAP EBITDA is a Non-GAAP financia l measure. 3. Based on trailing twelve months adjusted Non-GAAP EBITDA of $242M. Accelerate transformation into leading Rare Disease company Continued excellence in Generics R&D and operations Execute disciplined capital allocation strategy FINANCIAL STRENGTH 2026 STRATEGIC PRIORITIES Cash as of 3/31/26 $311M Net leverage as of 3/31/26(3) ~1.3x Projected 2026 total revenues(1) ~$1.1B Projected 2026 adjusted non- GAAP EBITDA(1)(2) ~$293M 27% YoY26% YoY

© 2026 ANI Pharmaceuticals, Inc. 28 Adjusted Non-GAAP diluted earnings per share calculation and US GAAP to Non-GAAP reconciliation 1. Adjusted non-GAAP Net Income Available to Common Shareholders excludes undistr ibuted earnings to participating securities. 2. Non-GAAP Adjusted Diluted Weighted-Average Shares Outstanding exclude certain dilutive shares rela ted to the senior convertible notes as they are intended to be covered by our capped call transactions. Our outstanding capped call transactions are intended to offset the dilutive effect of the senior convertible notes recognized in the calculation of GAAP diluted EPS in this repor ting per iod in full, and therefore 239,000 shares for the three months ended March 31, 2026, have been excluded from the calculation of the Non-GAAP Adjusted Diluted Weighted-Average Shares outstanding.

© 2026 ANI Pharmaceuticals, Inc. 29 References for Cortrophin Gel Addressable Patient Population Gout 1. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology (Oxford). 2019 Dec 1;58(12):2177-2180. doi: 10.1093/rheumatology/kez196. PMID: 31168609 2. Thorpe K. Partnership to fight chronic disease. May 21, 2018 3. Singh JA, Morlock A, Morlock R. Gout Flare Burden in the United States: A Multiyear Cross‐Sectional Survey Study. ACR Open Rheumatology. 2025 Jan;7(1):e11759, ANI claims data analysis (data on file), Proudman C, et al. Arthritis Res Ther. 2019;21:132. 4. Based on ANI claims analysis Multiple Sclerosis 5. Hittle M, Culpepper WJ, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Topol B, LaRocca NG, Nelson LM, Wallin MT. Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region. JAMA neurology. 2023 Jul 1;80(7):693-701. 6. Nazareth TA, Rava AR, Polyakov JL, Banfe EN, Waltrip II RW, Zerkowski KB, Herbert LB. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey. Multiple sclerosis and related disorders. 2018 Nov 1;26:219-34. 7. Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Burden of a multiple sclerosis relapse: the patient’s perspective. The Patient-Patient-Centered Outcomes Research. 2012 Mar;5(1):57-69. 8. Wynn D, Goldstick L, Bauer W, Zhao E, Tarau E, Cohen JA, Robertson D, Miller A. Results from a multicenter, randomized, double‐blind, placebo‐controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids. CNS Neuroscience & Therapeutics. 2022 Mar;28(3):364-71. Rheumatoid Arthritis 9. Evaluate Pharma, Evaluate Epi USA Population Insight 10. Bachman K. et al. J Rheumatol. 2018;45(11):1515-1521 11. Oh YJ, Moon KW. Predictors of flares in patients with rheumatoid arthritis who exhibit low disease activity: A nationwide cohort study. Journal of Clinical Medicine. 2020 Oct 7;9(10):3219. 12. Chikanza IC, Kozaci DL. Corticosteroid resistance in rheumatoid arthritis: molecular and cellular perspectives. Rheumatology. 2004 Nov 1;43(11):1337-45. Sarcoidosis 13. Baughman RP, et al. Ann Am Thorac Soc. 2016;13(8):1244-1252 14. Gerke AK, Judson MA, Cozier YC, Culver DA, Koth LL. Disease burden and variability in sarcoidosis. Annals of the American Thoracic Society. 2017 Dec;14(Supplement 6):S421-8. 15. Nam HH, Washington A, Butt M, Maczuga S, Guck D, Yanosky JD, Helm MF. The prevalence and geographic distribution of sarcoidosis in the United States. JAAD international. 2022 Dec 1;9:30-2. 16. Sangani R, Bosch NA, Govender P, Scarpato B, Walkey AJ, Newman J, Law AC, Gillmeyer KR, Shankar DA. Sarcoidosis treatment patterns in the United States: 2016-2022. Chest. 2025 Apr 1;167(4):1099-106. 17. ANI primary market research 2023 18. El Jammal T, Jamilloux Y, Gerfaud-Valentin M, Valeyre D, Sève P. Refractory sarcoidosis: a review. Therapeutics and clinical risk management. 2020 Apr 17:323-45. 19. Mahmood K, Butt NI, Ashfaq F, Younus R. Refractory Sarcoidosis. Journal of Ayub Medical College Abbottabad. 2023 Jul 9;35(3):479-81. Nephrotic Syndrome 20. Evaluate Pharma, Evaluate Epi USA Population Insight 21. Bensimhon AR, Williams AE, Gbadegesin RA. Treatment of steroid-resistant nephrotic syndrome in the genomic era. Pediatric nephrology. 2019 Nov;34(11):2279-93. / 22. Ghedira-Besbes L, Mallek A, Guediche MN. Idiopathic nephrotic syndrome in children: report of 57 cases. La Tunisie Medicale. 2003 Sep 1;81(9):702-8.

GRAPHIC

Filename: may2026anipcorporatepres001.jpg · Sequence: 6

Binary file (71500 bytes)

Download may2026anipcorporatepres001.jpg

GRAPHIC

Filename: may2026anipcorporatepres002.jpg · Sequence: 7

Binary file (276497 bytes)

Download may2026anipcorporatepres002.jpg

GRAPHIC

Filename: may2026anipcorporatepres003.jpg · Sequence: 8

Binary file (206082 bytes)

Download may2026anipcorporatepres003.jpg

GRAPHIC

Filename: may2026anipcorporatepres004.jpg · Sequence: 9

Binary file (118341 bytes)

Download may2026anipcorporatepres004.jpg

GRAPHIC

Filename: may2026anipcorporatepres005.jpg · Sequence: 10

Binary file (75051 bytes)

Download may2026anipcorporatepres005.jpg

GRAPHIC

Filename: may2026anipcorporatepres006.jpg · Sequence: 11

Binary file (138478 bytes)

Download may2026anipcorporatepres006.jpg

GRAPHIC

Filename: may2026anipcorporatepres007.jpg · Sequence: 12

Binary file (92864 bytes)

Download may2026anipcorporatepres007.jpg

GRAPHIC

Filename: may2026anipcorporatepres008.jpg · Sequence: 13

Binary file (84979 bytes)

Download may2026anipcorporatepres008.jpg

GRAPHIC

Filename: may2026anipcorporatepres009.jpg · Sequence: 14

Binary file (120382 bytes)

Download may2026anipcorporatepres009.jpg

GRAPHIC

Filename: may2026anipcorporatepres010.jpg · Sequence: 15

Binary file (50404 bytes)

Download may2026anipcorporatepres010.jpg

GRAPHIC

Filename: may2026anipcorporatepres011.jpg · Sequence: 16

Binary file (76420 bytes)

Download may2026anipcorporatepres011.jpg

GRAPHIC

Filename: may2026anipcorporatepres012.jpg · Sequence: 17

Binary file (90363 bytes)

Download may2026anipcorporatepres012.jpg

GRAPHIC

Filename: may2026anipcorporatepres013.jpg · Sequence: 18

Binary file (98503 bytes)

Download may2026anipcorporatepres013.jpg

GRAPHIC

Filename: may2026anipcorporatepres014.jpg · Sequence: 19

Binary file (146625 bytes)

Download may2026anipcorporatepres014.jpg

GRAPHIC

Filename: may2026anipcorporatepres015.jpg · Sequence: 20

Binary file (114450 bytes)

Download may2026anipcorporatepres015.jpg

GRAPHIC

Filename: may2026anipcorporatepres016.jpg · Sequence: 21

Binary file (128823 bytes)

Download may2026anipcorporatepres016.jpg

GRAPHIC

Filename: may2026anipcorporatepres017.jpg · Sequence: 22

Binary file (109468 bytes)

Download may2026anipcorporatepres017.jpg

GRAPHIC

Filename: may2026anipcorporatepres018.jpg · Sequence: 23

Binary file (83631 bytes)

Download may2026anipcorporatepres018.jpg

GRAPHIC

Filename: may2026anipcorporatepres019.jpg · Sequence: 24

Binary file (49167 bytes)

Download may2026anipcorporatepres019.jpg

GRAPHIC

Filename: may2026anipcorporatepres020.jpg · Sequence: 25

Binary file (135726 bytes)

Download may2026anipcorporatepres020.jpg

GRAPHIC

Filename: may2026anipcorporatepres021.jpg · Sequence: 26

Binary file (52205 bytes)

Download may2026anipcorporatepres021.jpg

GRAPHIC

Filename: may2026anipcorporatepres022.jpg · Sequence: 27

Binary file (90234 bytes)

Download may2026anipcorporatepres022.jpg

GRAPHIC

Filename: may2026anipcorporatepres023.jpg · Sequence: 28

Binary file (163689 bytes)

Download may2026anipcorporatepres023.jpg

GRAPHIC

Filename: may2026anipcorporatepres024.jpg · Sequence: 29

Binary file (46506 bytes)

Download may2026anipcorporatepres024.jpg

GRAPHIC

Filename: may2026anipcorporatepres025.jpg · Sequence: 30

Binary file (125710 bytes)

Download may2026anipcorporatepres025.jpg

GRAPHIC

Filename: may2026anipcorporatepres026.jpg · Sequence: 31

Binary file (46970 bytes)

Download may2026anipcorporatepres026.jpg

GRAPHIC

Filename: may2026anipcorporatepres027.jpg · Sequence: 32

Binary file (120036 bytes)

Download may2026anipcorporatepres027.jpg

GRAPHIC

Filename: may2026anipcorporatepres028.jpg · Sequence: 33

Binary file (109183 bytes)

Download may2026anipcorporatepres028.jpg

GRAPHIC

Filename: may2026anipcorporatepres029.jpg · Sequence: 34

Binary file (160046 bytes)

Download may2026anipcorporatepres029.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 36

v3.26.1

Cover

May 13, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

May 13, 2026

Entity Registrant Name

ANI PHARMACEUTICALS, INC.

Entity Incorporation, State or Country Code

Entity File Number

001-31812

Entity Tax Identification Number

58-2301143

Entity Address, Address Line One

104 Carnegie Center Drive, Suite 300

Entity Address, City or Town

Princeton

Entity Address, State or Province

Entity Address, Postal Zip Code

08540

City Area Code

609

Local Phone Number

759-1810

Title of 12(b) Security

Common Stock

Trading Symbol

ANIP

Security Exchange Name

NASDAQ

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Entity Central Index Key

0001023024

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration